Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660 · see citing works

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00056-2 · Cited by 1,878 · see citing works

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

Molina, J., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., Tremblay, C. L., Gall, J.-M. L., Cua, É., Pasquet, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506273 · Cited by 1,633 · see citing works

Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy.

Rodger, A. J., Cambiano, V., Bruun, T., Vernazza, P., Collins, S., van Lunzen, J., Corbelli, G. M., Estrada, V., Geretti, A. M., Beloukas, A., et al. (2016) · JAMA · doi:10.1001/jama.2016.5148 · Cited by 1,431 · see citing works

Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men

Anderson, P. L., Glidden, D. V., Liu, A., Buchbinder, S., Lama, J. R., Guanira, J. V., McMahan, V., Bushman, L. R., Casapía, M., Montoya, O., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004006 · Cited by 1,021 · see citing works

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Günthard, H., Saag, M., Benson, C., Rio, C. D., Eron, J., Gallant, J., Hoy, J., Mugavero, M., Sax, P., Thompson, M., et al. (2016) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2016.8900 · Cited by 847 · see citing works

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

Caskey, M. F., Klein, F., Lorenzi, J. C. C., Seaman, M. S., West, A. P., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J. F., et al. (2015) · Nature · doi:10.1038/nature14411 · Cited by 768 · see citing works

Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel

Thompson, M., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., Orrell, C., Altice, F. L., Bangsberg, D. R., Bartlett, J. G., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-11-201206050-00419 · Cited by 578 · see citing works

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Buti, M., Gane, E. J., Seto, W., Chan, H. L., Chuang, W., Stepanova, T., Hui, A. J., Lim, Y., Mehta, R. M., Janssen, H. L. A., et al. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30107-8 · Cited by 552 · see citing works

The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease

Freedberg, K. A., Losina, E., Weinstein, M. C., Paltiel, A. D., Cohen, C. J., Seage, G. R., Craven, D. E., Zhang, H., Kimmel, A. D., & Goldie, S. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441108 · Cited by 508 · see citing works

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

Margolis, D. A., González‐García, J., Stellbrink, H.-J., Eron, J. J., Yazdanpanah, Y., Podzamczer, D., Lutz, T., Angel, J. B., Richmond, G. J., Clotet, B., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31917-7 · Cited by 506 · see citing works

The Periodic Health Examination

Frappier-Davignon, L. (1934) · New England Journal of Medicine · doi:10.1056/nejm193401252100413 · Cited by 488 · see citing works

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

Caskey, M. F., Schoofs, T., Gruell, H., Settler, A., Karagounis, T. K., Kreider, E. F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T. Y., et al. (2017) · Nature Medicine · doi:10.1038/nm.4268 · Cited by 487 · see citing works

Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

Molina, J.-M., Charreau, I., Spire, B., Cotte, L., Chas, J., Capitant, C., Tremblay, C., Rojas-Castro, D., Cua, E., Pasquet, A., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30089-9 · Cited by 472 · see citing works

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Chan, H. L., Fung, S. K., Seto, W., Chuang, W., Chen, C.-Y., Kim, H. J., Hui, A. J., Janssen, H. L. A., Chowdhury, A., Tsang, T. Y. O., et al. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30024-3 · Cited by 467 · see citing works

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Sax, P. E., DeJesus, E., Mills, A., Zolopa, A. R., Cohen, C. J., Wohl, D. A., Gallant, J. E., Liu, H. C., Zhong, L., Yale, K., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60917-9 · Cited by 442 · see citing works

Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: A Systematic Review

Aidala, A. A., Wilson, M. G., Shubert, V., Gogolishvili, D., Globerman, J., Rueda, S., Bozack, A. K., Cabán, M., & Rourke, S. B. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302905 · Cited by 417 · see citing works

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Sax, P. E., Pozniak, A., Montes, M., Koenig, E., DeJesus, E., Stellbrink, H.-J., Antinori, A., Workowski, K., Slim, J., Reynes, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32340-1 · Cited by 394 · see citing works

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Gallant, J. E., Lazzarin, A., Mills, A., Orkin, C. M., Podzamczer, D., Tebas, P., Girard, P., Brar, I., Daar, E. S., Wohl, D. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32299-7 · Cited by 394 · see citing works

Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis.

Kuhar, D. T., Henderson, D. K., Struble, K. A., Heneine, W., Thomas, V., Cheever, L. W., Gomaa, A., Panlilio, A. L., & US Public Health Service Working Group (2013) · Infection Control & Hospital Epidemiology · doi:10.1086/672271 · Cited by 377 · see citing works

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth

Huang, J., Kang, B. H., Ishida, E., Zhou, T., Griesman, T., Sheng, Z., Wu, F., Doria‐Rose, N. A., Zhang, B., McKee, K., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.027 · Cited by 368 · see citing works

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Llibre, J. M., Hung, C., Brinson, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33095-7 · Cited by 361 · see citing works

Initiating Antiretroviral Therapy for HIV at a Patient’s First Clinic Visit: The RapIT Randomized Controlled Trial

Rosen, S. B., Maskew, M., Fox, M. P., Nyoni, C., Mongwenyana, C., Malete, G., Sanne, I., Bokaba, D., Sauls, C., Rohr, J. K., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002015 · Cited by 328 · see citing works

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

Gandhi, R. T., Zheng, L., Bosch, R. J., Chan, E. S., Margolis, D. M., Read, S., Kallungal, B., Palmer, S., Medvik, K., Lederman, M. M., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000321 · Cited by 305 · see citing works

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine

Cottrell, M. L., Yang, K. H., Prince, H. M. A., Sykes, C., White, N., Malone, S., Dellon, E. S., Madanick, R. D., Shaheen, N. J., Hudgens, M. G., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw077 · Cited by 298 · see citing works

Benefits and risks of rapid initiation of antiretroviral therapy

Ford, N. P., Migone, C., Calmy, A., Kerschberger, B., Kanters, S., Nsanzimana, S., Mills, E. J., Meintjes, G., Vitória, M., Doherty, M. C., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001671 · Cited by 291 · see citing works

Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial

Koenig, S. P., Dorvil, N., Dévieux, J. G., Hedt‐Gauthier, B., Riviere, C., Faustin, M., Lavoile, K., Perodin, C., Apollon, A., Duverger, L., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002357 · Cited by 282 · see citing works

The periodic health examination. Canadian Task Force on the Periodic Health Examination.

(1979) · PubMed Central · Cited by 281 · see citing works

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy

Hunt, P. W., Deeks, S. G., Rodriguez, B. A., Valdez, H., Shade, S. B., Abrams, D. I., Kitahata, M. M., Krone, M., Neilands, T. B., Brand, R., et al. (2003) · AIDS · doi:10.1097/00002030-200309050-00009 · Cited by 273 · see citing works

Cost-Effectiveness of HIV Treatment in Resource-Poor Settings — The Case of Côte d'Ivoire

Goldie, S. J., Yazdanpanah, Y., Losina, E., Weinstein, M. C., Anglaret, X., Walensky, R. P., Hsu, H., Kimmel, A. D., Holmes, C. B., Kaplan, J. E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa060247 · Cited by 272 · see citing works

Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho

Labhardt, N. D., Ringera, I. K., Lejone, T. I., Klimkait, T., Muhairwe, J. A., Amstutz, A., & Glass, T. R. (2018) · JAMA · doi:10.1001/jama.2018.1818 · Cited by 261 · see citing works

The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting

Pilcher, C. D., Ospina-Norvell, C., Dasgupta, A., Jones, D., Hartogensis, W., Torres, S. R., Calderon, F., DeMicco, E., Geng, E. H., Gandhi, M., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001134 · Cited by 244 · see citing works

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

Gaudinski, M. R., Coates, E. E., Houser, K. V., Chen, G. L., Yamshchikov, G. V., Saunders, J. G., Holman, L. A., Gordon, I. J., Plummer, S. H., Hendel, C. S., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002493 · Cited by 241 · see citing works

Recommendations for HIV Screening of Gay, Bisexual, and Other Men Who Have Sex with Men — United States, 2017

DiNenno, E. A., Prejean, J., Irwin, K. L., Delaney, K. P., Bowles, K. E., Martin, T., Tailor, A., Dumitru, G. G., Mullins, M. M., Hutchinson, A. B., et al. (2017) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6631a3 · Cited by 238 · see citing works

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis

Tan, D. H. S., Hull, M., Yoong, D., Tremblay, C. L., O’Byrne, P., Thomas, R., Kille, J., Baril, J.-G., Cox, J., Giguère, P., et al. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170494 · Cited by 214 · see citing works

Identification and specificity of broadly neutralizing antibodies against HIV

McCoy, L. E., & Burton, D. R. (2017) · Immunological Reviews · doi:10.1111/imr.12484 · Cited by 213 · see citing works

Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel

Günthard, H. F., Cálvez, V., Paredes, R., Pillay, D., Shafer, R. W., Wensing, A. M. J., Jacobsen, D. M., & Richman, D. D. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy463 · Cited by 209 · see citing works

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Molina, J., Ward, D. J., Brar, I., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30092-4 · Cited by 205 · see citing works

Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use

Metsch, L. R., Feaster, D. J., Gooden, L. K., Matheson, T., Stitzer, M. L., Das, M., Jain, M. K., Rodriguez, A. E., Armstrong, W. S., Lucas, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.8914 · Cited by 191 · see citing works

Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000–2010

Buchacz, K. A., Buchacz, K., Lau, B. M., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw085 · Cited by 185 · see citing works

The Periodic Health Examination: 1980

Delbanco, T. L., & TAYLOR, W. C. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-2-251 · Cited by 183 · see citing works

Vital Signs: Human Immunodeficiency Virus Testing and Diagnosis Delays — United States

Dailey, A. F., Hoots, B., Hall, H. I., Song, R., Hayes, D., Fulton, P., Prejean, J., Hernandez, A. L., Koenig, L. J., & Valleroy, L. A. (2017) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6647e1 · Cited by 181 · see citing works

Brief Report

Wohl, D. A., Oka, S., Clumeck, N., Clarke, A. E., Brinson, C. C., Stephens, J. L., Tashima, K. T., Arribas, J. R., Rashbaum, B., Chéret, A., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000940 · Cited by 179 · see citing works

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Daar, E. S., DeJesus, E., Ruane, P. J., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30091-2 · Cited by 179 · see citing works

U=U taking off in 2017

The Lancet, H. I. V. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30183-2 · Cited by 174 · see citing works

Beyond Core Indicators of Retention in HIV Care: Missed Clinic Visits Are Independently Associated With All-Cause Mortality

Mugavero, M. J., Westfall, A. O., Cole, S. R., Geng, E. H., Crane, H. M., Kitahata, M. M., Mathews, W. C., Napravnik, S., Eron, J. J., Moore, R. D., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu603 · Cited by 173 · see citing works

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

Gallant, J. E., Daar, E. S., Raffi, F., Brinson, C. C., Ruane, P. J., DeJesus, E., Johnson, M. A., Clumeck, N., Osiyemi, O. O., Ward, D., et al. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)00024-2 · Cited by 165 · see citing works

Association of Increased Chronicity of Depression With HIV Appointment Attendance, Treatment Failure, and Mortality Among HIV-Infected Adults in the United States

Pence, B. W., Mills, J. C., Bengtson, A. M., Gaynes, B. N., Breger, T. L., Cook, R. L., Moore, R. D., Grelotti, D. J., O’Cleirigh, C. M., & Mugavero, M. J. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4726 · Cited by 155 · see citing works

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Molina, J., Squires, K., Sax, P. E., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30021-3 · Cited by 150 · see citing works

Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial

Amanyire, G., Semitala, F. C., Namusobya, J., Katuramu, R., Kampiire, L., Wallenta, J., Charlebois, E., Camlin, C., Kahn, J., Chang, W., et al. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30090-x · Cited by 141 · see citing works

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Hill, A. M., Hughes, S. L., Gotham, D., & Pozniak, A. (2018) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30248-x · Cited by 139 · see citing works

The future role of CD4 cell count for monitoring antiretroviral therapy

Ford, N. P., Meintjes, G., Pozniak, A., Bygrave, H., Hill, A. M., PETER, T. F., Davies, M., Grinsztejn, B. G. J., Calmy, A., Kumarasamy, N., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70896-5 · Cited by 138 · see citing works

MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection.

Hoornenborg, E., Achterbergh, R. C. A., Schim van der Loeff, M. F., Davidovich, U., Hogewoning, A., de Vries, H. J. C., Schinkel, J., Prins, M., & van de Laar, T. J. W. (2017) · AIDS · doi:10.1097/qad.0000000000001522 · Cited by 137 · see citing works

Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States

Walensky, R. P., Sax, P. E., Nakamura, Y., Weinstein, M. C., Pei, P. P., Freedberg, K. A., Paltiel, A. D., & Schackman, B. R. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-2-201301150-00002 · Cited by 130 · see citing works

Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes

Kong, R., Louder, M. K., Wagh, K., Bailer, R. T., deCamp, A. C., Greene, K., Gao, H., Taft, J. D., Gazumyan, A., Liu, C., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03136-14 · Cited by 129 · see citing works

Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012–2013

Crepaz, N., Tang, T., Marks, G. N., Mugavero, M. J., Espinoza, L., & Hall, H. I. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw418 · Cited by 129 · see citing works

Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients: A Randomized Clinical Trial (HPTN 065)

El-Sadr, W. M., Donnell, D., Beauchamp, G., Hall, H. I., Torian, L. V., Zingman, B., Lum, G., Kharfen, M., Elion, R., Leider, J., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.2158 · Cited by 127 · see citing works

Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications

Marzolini, C., Gibbons, S., Khoo, S., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw032 · Cited by 124 · see citing works

Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016

(2016) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2016.06.028 · Cited by 124 · see citing works

Comprehensive and Medically Appropriate Food Support Is Associated with Improved HIV and Diabetes Health

Palar, K., Nápoles, T. M., Hufstedler, L. L., Seligman, H. K., Hecht, F. M., Madsen, K., Ryle, M., Pitchford, S., Frongillo, E. A., & Weiser, S. D. (2017) · Journal of Urban Health · doi:10.1007/s11524-016-0129-7 · Cited by 120 · see citing works

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results

Arribas, J. R., Thompson, M., Sax, P. E., Haas, B. J., McDonald, C., Wohl, D. A., DeJesus, E., Clarke, A. E., Guo, S., Wang, H., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001350 · Cited by 120 · see citing works

Association Between Internalized HIV-Related Stigma and HIV Care Visit Adherence

Rice, W. S., Crockett, K. B., Mugavero, M. J., Raper, J. L., Atkins, G. C., & Turan, B. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001543 · Cited by 116 · see citing works

Implementation of a Rapid Entry Program Decreases Time to Viral Suppression Among Vulnerable Persons Living With HIV in the Southern United States

Colasanti, J. A., Sumitani, J., Mehta, C. C., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy104 · Cited by 115 · see citing works

Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial

Wijting, I. E. A., Rokx, C., Boucher, C. A., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30152-2 · Cited by 113 · see citing works

The Future of HIV Testing

Branson, B. M. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181fbca44 · Cited by 112 · see citing works

Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009–2012

Hurt, C. B., Sebastian, J., Hicks, C. B., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit697 · Cited by 111 · see citing works

The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion

Donnell, D. J., Ramos, E. M., Celum, C., Baeten, J. M., Dragavon, J., Tappero, J. W., Lingappa, J. R., Ronald, A., Fife, K. H., & Coombs, R. W. (2017) · AIDS · doi:10.1097/qad.0000000000001577 · Cited by 110 · see citing works

Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis

Knox, D. C., Anderson, P. L., Harrigan, P. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1611639 · Cited by 109 · see citing works

Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

Trottier, B., Lake, J. E., Logue, K., et al. (2016) · Antiviral Therapy · doi:10.3851/imp3166 · Cited by 108 · see citing works

Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens

Clay, P. G., Nag, S., Graham, C. M., & Narayanan, S. (2015) · Medicine · doi:10.1097/md.0000000000001677 · Cited by 107 · see citing works

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

Pulido, F., Ribera, E., Lagarde, M., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix734 · Cited by 103 · see citing works

Is It Safe to Discontinue PrimaryPneumocystis jiroveciPneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/μL?

The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) (2010) · Clinical Infectious Diseases · doi:10.1086/655761 · Cited by 101 · see citing works

HIV Incidence Among Men Who Have Sex With Men After Diagnosis With Sexually Transmitted Infections

Katz, D. A., Dombrowski, J. C., Bell, T. R., Kerani, R. P., & Golden, M. R. (2016) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000423 · Cited by 98 · see citing works

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Orkin, C. M., Molina, J., Negredo, E., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30179-0 · Cited by 97 · see citing works

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA <500000 Copies/mL

Taiwo, B., Zheng, L., Stefanescu, A. R., Nyaku, A. N., Bezins, B., Wallis, C. L., Godfrey, C. C., Sax, P. E., Acosta, E. P., Haas, D. W., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix1083 · Cited by 93 · see citing works

Frequency and Spectrum of Unexpected Clinical Manifestations of Primary HIV-1 Infection

Braun, D. L., Kouyos, R. D., Balmer, B., Grube, C., Weber, R. K., & Günthard, H. F. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ398 · Cited by 92 · see citing works

Association between Perceived Discrimination in Healthcare Settings and HIV Medication Adherence: Mediating Psychosocial Mechanisms

Turan, B., Rogers, A. J., Rice, W. S., Atkins, G. C., Cohen, M. H., Wilson, T. E., Adimora, A. A., Merenstein, D. J., Adedimeji, A., Wentz, E., et al. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1957-5 · Cited by 88 · see citing works

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial

Taiwo, B., Marconi, V. C., Berzins, B., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix1131 · Cited by 86 · see citing works

Announcement: Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV — United States, 2016

(2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6517a5 · Cited by 85 · see citing works

Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young Black MSM in Chicago

Lancki, N., Almirol, E. A., Alon, L., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001710 · Cited by 84 · see citing works

Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report

Hoornenborg, E., Prins, M., Achterbergh, R., Woittiez, L. R., Cornelissen, M. T. E., Jurriaans, S., Kootstra, N. A., Anderson, P. L., Reiss, P., de Vries, H. J. C., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30132-7 · Cited by 79 · see citing works

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades

Doyle, T., Dunn, D., Ceccherini‐Silberstein, F., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv243 · Cited by 77 · see citing works

Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)

Giambenedetto, S. D., Fabbiani, M., Quirós-Roldán, E., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw557 · Cited by 77 · see citing works

Recent trends and patterns in HIV ‐1 transmitted drug resistance in the United Kingdom

Tostevin, A., White, E., Dunn, D., et al. (2016) · HIV Medicine · doi:10.1111/hiv.12414 · Cited by 75 · see citing works

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

Orkin, C. M., DeJesus, E., Ramgopal, M. N., Crofoot, G. E., Ruane, P. J., LaMarca, A., Mills, A., Vandercam, B., de Wet, J. J., Rockstroh, J. K., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30031-0 · Cited by 75 · see citing works

Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis

Markowitz, M. H., Grossman, H. A., Anderson, P. L., Grant, R. M., Gandhi, M., Horng, H., & Mohri, H. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001534 · Cited by 75 · see citing works

Improved HIV-related outcomes associated with implementation of a novel public health information exchange

Magnus, M., Herwehe, J., Gruber, D., Wilbright, W., Shepard, E., Abrams, A., Foxhood, J., Smith, L., Xiao, K., DeYoung, K., et al. (2012) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2012.06.005 · Cited by 73 · see citing works

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

BRENNER, B. G., Thomas, R., Blanco, J. L., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw071 · Cited by 73 · see citing works

Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis

Mugwanya, K. K., Wyatt, C. M., Celum, C., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000868 · Cited by 70 · see citing works

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults

Gallant, J. E., Brunetta, J. M., Crofoot, G. E., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001069 · Cited by 69 · see citing works

Effectiveness of a combination strategy for linkage and retention in adult HIV care in Swaziland: The Link4Health cluster randomized trial

McNairy, M. L., Lamb, M. R., Gachuhi, A. B., Nuwagaba‐Biribonwoha, H., Burke, S. A., Mazibuko, S., Okello, V., Ehrenkranz, P. D., Sahabo, R., & El-Sadr, W. M. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002420 · Cited by 69 · see citing works

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

Girouard, M. P., Sax, P. E., Parker, R. A., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ981 · Cited by 68 · see citing works

Lack of Resistance to Integrase Inhibitors among Antiretroviral-Naive Subjects with Primary HIV-1 Infection, 2007–2013

Stekler, J. D., McKernan, J. L., Milne, R. S., et al. (2014) · Antiviral Therapy · doi:10.3851/imp2780 · Cited by 66 · see citing works

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

Pérez-Molina, J. A., Rubio, R., Rivero, A., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw379 · Cited by 65 · see citing works

A combination intervention strategy to improve linkage to and retention in HIV care following diagnosis in Mozambique: A cluster-randomized study

Elul, B., Lamb, M. R., Lahuerta, M., Abacassamo, F., Ahoua, L., Kujawski, S. A., Tomo, M., & Jani, I. V. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002433 · Cited by 64 · see citing works

Tailored Nutrition Education and Food Assistance Improve Adherence to HIV Antiretroviral Therapy: Evidence from Honduras

Martı́nez, H., Palar, K., Linnemayr, S., Smith, A. C., Derose, K. P., Ramírez, B., Farías, H., & Wagner, G. J. (2014) · AIDS and Behavior · doi:10.1007/s10461-014-0786-z · Cited by 62 · see citing works

Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies

Fuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61 · see citing works

Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug–Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine

Brooks, K. M., George, J. M., Pau, A. K., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy082 · Cited by 59 · see citing works

Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV

Elion, R., Althoff, K. N., Zhang, J., Moore, R. D., Gange, S. J., Kitahata, M. M., Crane, H. M., Drozd, D. R., Stein, J. H., Klein, M. B., et al. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001642 · Cited by 56 · see citing works

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

Huhn, G. D., Tebas, P., Gallant, J. E., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001193 · Cited by 55 · see citing works

Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments

Crowell, T. A., Colby, D. J., Pinyakorn, S., Fletcher, J. L. K., Kroon, E., Schuetz, A., Krebs, S. J., Slike, B. M., Leyre, L., Chomont, N., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1063 · Cited by 55 · see citing works

A Randomized Trial to Test a Peer Mentor Intervention to Improve Outcomes in Persons Hospitalized With HIV Infection

Giordano, T. P., Cully, J. A., Amico, K. R., Davila, J. A., Kallen, M. A., Hartman, C. M., Wear, J., Buscher, A. L., & Stanley, M. A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw322 · Cited by 53 · see citing works

Mortality Risk After AIDS-Defining Opportunistic Illness Among HIV-Infected Persons—San Francisco, 1981–2012

Djawe, K., Buchacz, K. A., Hsu, L. C., Chen, M.-J., Selik, R. M., Rose, C. E., Williams, T., Brooks, J. T., & Schwarcz, S. K. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv235 · Cited by 52 · see citing works

Using technology to support HIV self-testing among MSM

LeGrand, S., Muessig, K. E., Horvath, K. J., Rosengren, A. L., & Hightow‐Weidman, L. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000400 · Cited by 52 · see citing works

Food Insecurity is Associated with Poor HIV Outcomes Among Women in the United States

Spinelli, M. A., Frongillo, E. A., Sheira, L. A., et al. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1968-2 · Cited by 47 · see citing works

Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study

Scherrer, A., Yang, W.-L., Kouyos, R. D., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw165 · Cited by 46 · see citing works

Odds of Viral Suppression by Single‐Tablet Regimens, Multiple‐Tablet Regimens, and Adherence Level in HIV / AIDS Patients Receiving Antiretroviral Therapy

Sutton, S. S., Magagnoli, J., & Hardin, J. W. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1889 · Cited by 46 · see citing works

The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.

Jain, S., Krakower, D., & Mayer, K. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ094 · Cited by 45 · see citing works

90-90-90-Plus: Maintaining Adherence to Antiretroviral Therapies

Corless, I. B., Hoyt, A., Tyer‐Viola, L. A., Sefcik, E. F., Kemppainen, J. K., Holzemer, W. L., Eller, L. S., Nokes, K. M., Phillips, J. C., Dawson-Rose, C. S., et al. (2017) · AIDS Patient Care and STDs · doi:10.1089/apc.2017.0009 · Cited by 42 · see citing works

Association of early HIV viremia with mortality after HIV-associated lymphoma

Gopal, S., Patel, M. R., Yanik, E. L., et al. (2013) · AIDS · doi:10.1097/qad.0b013e3283635232 · Cited by 40 · see citing works

Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA

Zaccarelli, M., Santoro, M. M., Armenia, D., et al. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2016.07.007 · Cited by 40 · see citing works

Implementing data-to-care initiatives for HIV in New York state: assessing the value of community health centers identifying persons out of care for health department follow-up

Hart-Malloy, R., Brown, S., Bogucki, K., et al. (2017) · AIDS Care · doi:10.1080/09540121.2017.1363851 · Cited by 33 · see citing works

Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial

Girard, P., Antinori, A., Arribas, J. R., et al. (2016) · HIV Medicine · doi:10.1111/hiv.12386 · Cited by 31 · see citing works

Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection

Ambrosioni, J., Nicolás, D., Manzardo, C., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw376 · Cited by 31 · see citing works

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial

Post, F. A., Yazdanpanah, Y., Schembri, G., et al. (2017) · HIV Clinical Trials · doi:10.1080/15284336.2017.1291867 · Cited by 31 · see citing works

CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART

Sauter, R., Huang, R., Ledergerber, B., et al. (2016) · Medicine · doi:10.1097/md.0000000000005094 · Cited by 30 · see citing works

Predictors of CD4 health and viral suppression outcomes for formerly homeless people living with HIV/AIDS in scattered site supportive housing

Bowen, E. A., Canfield, J., Moore, S., Hines, M., Hartke, B., & Rademacher, C. (2017) · AIDS Care · doi:10.1080/09540121.2017.1307920 · Cited by 28 · see citing works

Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?

Koullias, Y., Sax, P. E., Fields, N. F., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix542 · Cited by 28 · see citing works

Assessment of HIV Screening Tests for Pre-Exposure Prophylaxis Programs

Delaugerre, C., Antoni, G., Mahjoub, N., Pialoux, G., Cua, É., Pasquet, A., Hall, N., Tremblay, C. L., Cotte, L., Capitant, C., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix297 · Cited by 28 · see citing works

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

Lambert-Niclot, S., George, E. C., Pozniak, A. L., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv427 · Cited by 26 · see citing works

Increasing the Clinical Potential and Applications of Anti-HIV Antibodies

Hua, C. K., & Ackerman, M. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01655 · Cited by 26 · see citing works

Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life

Boesch, A. W., Alter, G., & Ackerman, M. E. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000149 · Cited by 22 · see citing works

Is Primary Mycobacterium avium Complex Prophylaxis Necessary in Patients with CD4 <50 Cells/μL Who Are Virologically Suppressed on cART?

Yangco, B. G., Buchacz, K. A., Baker, R. K., et al. (2014) · AIDS Patient Care and STDs · doi:10.1089/apc.2013.0270 · Cited by 20 · see citing works

High HIV incidence in men who have sex with men following an early syphilis diagnosis: is there room for pre-exposure prophylaxis as a prevention strategy?

Girometti, N., Gutiérrez, Á., Nwokolo, N. C., McOwan, A., & Whitlock, G. G. (2016) · Sexually Transmitted Infections · doi:10.1136/sextrans-2016-052865 · Cited by 19 · see citing works

The Epi-TAF for Tenofovir Disoproxil Fumarate?: Table 1.

Walensky, R. P., Horn, T. H., & Paltiel, A. D. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ1000 · Cited by 18 · see citing works

Screening for acute HIV infection in community-based settings: Cost-effectiveness and impact on transmissions

Hoenigl, M., Chaillon, A., Mehta, S. R., Smith, D. M., Zivin, J. G., & Little, S. J. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.07.019 · Cited by 18 · see citing works

Hospital‐based routine HIV testing in high‐income countries: a systematic literature review

Elgalib, A., Fidler, S. J., & Sabapathy, K. (2017) · HIV Medicine · doi:10.1111/hiv.12568 · Cited by 18 · see citing works

Cost-Effectiveness of Newer Antiretroviral Drugs in Treatment-Experienced Patients With Multidrug-Resistant HIV Disease

Bayoumi, A. M., Barnett, P. G., Joyce, V. R., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000002 · Cited by 16 · see citing works

Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression

Mills, J. C., Harman, J. S., Cook, R. L., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001618 · Cited by 15 · see citing works

Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen

Armenia, D., Carlo, D. D., Calcagno, A., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw512 · Cited by 12 · see citing works

Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals

Negredo, E., Estrada, V., Domingo, P., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw504 · Cited by 11 · see citing works

Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial

Galli, L., Galli, L., Spagnuolo, V., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw031 · Cited by 10 · see citing works

Sexually Transmitted Infections Treatment Guidelines, 2021

Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 2,759 · see citing works

Dolutegravir plus two different prodrugs of tenofovir to treat HIV

Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902824 · Cited by 723 · see citing works

Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance

Malet, I., Ambrosio, F. A., Subra, F., Herrmann, B., Leh, H., Bouger, M.-C., Artese, A., Katlama, C., Talarico, C., Romeo, I., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx529 · Cited by 20 · see citing works

End resistance to dolutegravir roll-out

The Lancet, H. I. V. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30231-9 · Cited by 33 · see citing works

Emergence of Acquired Dolutegravir Resistance in Treatment-Experienced People with HIV in LesothoPreprint

Tschumi, N., Lukau, B., Tlali, K., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4683840 · Cited by 2 · see citing works

Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations

Cattaneo, D., Pagano, S., Colombo, M. L., Giacomelli, A., Gori, A., & Gervasoni, C. (2024) · AIDS · doi:10.1097/qad.0000000000003843 · Cited by 5 · see citing works

Emergence of Acquired Dolutegravir Resistance in Treatment-experienced People With HIV in Lesotho

Tschumi, N., Lukau, B., Tlali, K., Motaboli, L., Kao, M., Kopo, M., Haenggi, K., Mokebe, M., Naegele, K., Ayakaka, I., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae185 · Cited by 35 · see citing works